Genfit Addresses Multiple Transition Issues With CEO Change
Co-founder and CEO Mouney will turn over the reins to former GSK and Lilly exec Pascal Prigent in mid-September.
You may also be interested in...
As Genfit nears Phase III data for its NASH candidate elafibranor, it has promoted a new CEO and is working ahead on both an NDA filing and facing the commercial challenges of a new therapeutic space.
French company expects Phase III data later in 2019 that will demonstrate elafibranor’s ability to resolve NASH without worsening of fibrosis. Genfit also is partnered with Covance on a potential diagnostic test for NASH.
Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.